全球化与AI浪潮涌来，医药企业寻找“可持续创新”共识

Group 1 - The core viewpoint of the forum emphasizes that the sustainable innovation path for Chinese innovative pharmaceutical companies lies not only in "going out" and "bringing in," but also in finding breakthroughs in sustainability [2] - Chinese innovative pharmaceutical companies face significant challenges in international expansion, including regulatory communication, indication selection, and clinical verification, which test their resource allocation and long-term strategic capabilities [2] - Multinational pharmaceutical companies are accelerating localization in the Chinese market, requiring more flexible strategic implementation and deep local cooperation to respond to the rapid development of domestic innovation [2] Group 2 - Organizational structure, talent systems, and management language discrepancies often lead to internal friction for Chinese pharmaceutical companies during their internationalization process [3] - AI technology is rapidly penetrating pharmaceutical companies' commercialization, research and development, and compliance processes, reshaping management boundaries [3] - The relationship between localization and globalization is highlighted as essential for stability and enhancing strategic positioning, with sustainability being a prerequisite for long-term value [3]